Explore more publications!
North Dakota Technology Review
Got News to Share?

North Dakota Technology Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Dakota Technology Review.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 29, 2025

Core AI Announces Divestiture of Siyata Mobile and Subsidiaries
December 29, 2025

Core AI Announces Divestiture of Siyata Mobile and Subsidiaries

Indeterminate GlobeNewswire
BiomX Announces $3.0 Million Private Placement
December 29, 2025

BiomX Announces $3.0 Million Private Placement

Indeterminate GlobeNewswire
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
December 29, 2025

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Indeterminate GlobeNewswire
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
December 29, 2025

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Indeterminate GlobeNewswire
Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico
December 29, 2025

Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico

Indeterminate GlobeNewswire
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
December 29, 2025

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Indeterminate GlobeNewswire
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
December 29, 2025

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Indeterminate GlobeNewswire
Rezolve Ai Unveils New SQD Revenue Model Backed by Enterprise Customers
December 29, 2025

Rezolve Ai Unveils New SQD Revenue Model Backed by Enterprise Customers

Indeterminate GlobeNewswire
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
December 29, 2025

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Indeterminate GlobeNewswire
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
December 29, 2025

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Indeterminate GlobeNewswire
Datavault AI Inc. Announces Proposed Dividend of Warrants
December 29, 2025

Datavault AI Inc. Announces Proposed Dividend of Warrants

Indeterminate GlobeNewswire
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
December 29, 2025

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Indeterminate GlobeNewswire
illumin Announces TSX Acceptance of Normal Course Issuer Bid
December 29, 2025

illumin Announces TSX Acceptance of Normal Course Issuer Bid

Indeterminate GlobeNewswire
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
December 29, 2025

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Indeterminate GlobeNewswire
Biptap Sets the Stage for Omnibanking in 2026
December 29, 2025

Biptap Sets the Stage for Omnibanking in 2026

Indeterminate GlobeNewswire
ONAR, a Leading AI Marketing Company, Closes a Record Year with New December Clients Adding Over $400,000 in Recurring Revenue
December 29, 2025

ONAR, a Leading AI Marketing Company, Closes a Record Year with New December Clients Adding Over $400,000 in Recurring Revenue

Indeterminate GlobeNewswire
Gogo confirms next-generation air-to-ground 5G now launched.
December 29, 2025

Gogo confirms next-generation air-to-ground 5G now launched.

Indeterminate GlobeNewswire
Ourbit SuperCEX Closes “Cosmic Wheel” with $2.6M in Rewards and NFT-Based User Incentives
December 29, 2025

Ourbit SuperCEX Closes “Cosmic Wheel” with $2.6M in Rewards and NFT-Based User Incentives

Indeterminate GlobeNewswire
Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI
December 29, 2025

Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI

Indeterminate GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
December 29, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions